Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Eli Lilly reported FY 2025 revenue of $65.2B, up 44.7%, and net income of $20.6B; Pfizer generated $62.6B in revenue, down 1.6%, and $7.8B in net income. Lilly’s six leading drugs accounted for about 82% of sales, while its forward P/E of 31.2x and P/S of 13.5x were well above Pfizer’s 9.3x and 2.5x. The article favors Lilly for 2026, citing strong GLP-1 demand, a recent earnings beat and raised outlook, while noting concentration, pricing and patent risks across the companies.

Analysis

The key swing factor is not simply demand for obesity drugs; it is how much of that demand converts into reimbursed, recurring prescriptions. CVS Health’s coverage choices illustrate payer leverage: tighter formularies can slow volume even when clinical interest remains strong, while broader access or effective oral options could expand the addressable pool. Watch coverage terms and prescription persistence, not just launch or demand headlines.

For Eli Lilly, high product concentration cuts both ways: successful manufacturing expansion and access gains can produce operating leverage, but any payer restriction, supply disruption, or disappointing evidence can transmit quickly into growth expectations. Novo Nordisk is the most direct competitive check; oral efficacy, tolerability, and net pricing may matter more than headline launch dates. Pfizer’s obesity entry is optionality, not yet a demonstrated offset to its patent-transition risk. Its low valuation should not be treated as a floor until acquired assets show commercial contribution and the earnings base proves durable.

Near term, payer decisions and clinical/regulatory readouts can drive sharp relative moves. Over 1–3 months, verify Lilly prescription trends, access, and supply alongside Pfizer pipeline milestones. Over 6–18 months, the central question is whether oral therapies broaden the market or mainly redistribute share, while patent erosion tests Pfizer’s cash-generation and dividend capacity. The contrarian risk to a Lilly-over-Pfizer consensus is that expectations already capitalize sustained leadership; a modest access or execution miss could compress the premium. The source’s growth claims do not independently establish future realized sales.

Key Decisions for Investors

• Prefer Eli Lilly over Pfizer on a relative basis, but scale in only after confirming prescription growth is translating into reimbursed volume and supply availability; avoid chasing momentum without those checks.
• Treat Pfizer as a watchlist/value position rather than a presumed bargain. Reassess after evidence that acquired oncology assets and obesity programs contribute meaningfully enough to offset patent-related erosion; monitor cash flow and dividend coverage.
• Track CVS Health formulary decisions and coverage changes as an early warning for obesity-drug access, and compare the resulting prescription and persistence data across Eli Lilly and Novo Nordisk.
• Falsify the relative Lilly thesis if access restrictions or supply constraints materially weaken prescription trends, or if clinical/commercial evidence shows oral competitors taking share without expanding the market. Revisit Pfizer’s downside thesis if pipeline milestones and reported results demonstrate durable growth that offsets upcoming expirations.